A new research paper titled "BCAS1 defines a heterogeneous cell population in diffuse gliomas" has been published in Oncotarget. Oligodendrocyte precursor markers have become of great interest to ...
Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...
Diffuse gliomas are malignant brain tumors and cannot be optimally examined by conventional imaging using MRI. Amino acid PET can better visualize the activity and spread of gliomas. An international ...
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials Histone 3 (H3) K27M–mutant diffuse ...
Dordaviprone has been granted Priority Review by the FDA for recurrent H3 K27M-mutant diffuse glioma, with a target action date of August 18. The drug has received Rare Pediatric Disease, Fast-Track, ...
Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...
The late 'Walking Dead' alum died following a months-long battle with a rare form of brain cancer.
Figure 2: BCAS1 + cells in diffuse gliomas are morphologically different from BCAS1 + cells in healthy brain tissue. Oligodendrocyte precursor markers have become of great interest to identify new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results